RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.
What is the ticker symbol for RenovoRx, Inc.? What does RNXT stand for in stocks?
RNXT is the stock ticker symbol of RenovoRx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of RenovoRx, Inc. (RNXT)?
As of Fri Nov 22 2024, market cap of RenovoRx, Inc. is 30.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of RNXT stock?
You can check RNXT's fair value in chart for subscribers.
Is RenovoRx, Inc. a good stock to buy?
The fair value guage provides a quick view whether RNXT is over valued or under valued. Whether RenovoRx, Inc. is cheap or expensive depends on the assumptions which impact RenovoRx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RNXT.